Rociletinib/Osimertinib for EGFR T790M-negative NSCLC

Apr 20, 2016 · 5m 19s
Rociletinib/Osimertinib for EGFR T790M-negative NSCLC
Description
Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.
Information
Author cancerGRACE
Organization cancerGRACE
Website -
Tags

Looks like you don't have any active episode

Browse Spreaker Catalogue to discover great new content

Current

Podcast Cover

Looks like you don't have any episodes in your queue

Browse Spreaker Catalogue to discover great new content

Next Up

Episode Cover Episode Cover

It's so quiet here...

Time to discover new episodes!

Discover
Your Library
Search